EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer

Anna S Koerner iD, Ryan H Moy, Sandra W Ryeom iD, Sam S Yoon

Cancers · 15.08.2023 · 15 (16) · 4114

DOI: 10.3390/cancers15164114 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.08.2023. Verfasst von Anna S Koerner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Herbert Irving Columba Cancer Center Support Grant, DeGregorio Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer is a highly prevalent and lethal disease worldwide. Given the insidious nature of the presenting symptoms, patients are frequently diagnosed with advanced, unresectable disease. However, many patients will present with locally advanced gastric cancer (LAGC), which is often defined as the primary tumor extending beyond the muscularis propria (cT3-T4) or having nodal metastases (cN+) disease and without distant metastases (cM0). LAGC is typically treated with surgical resection and perioperative chemotherapy. The treatment of LAGC remains a challenge, given the heterogeneity of this disease, and the optimal multimodal treatment regimen may be different for different LAGC subtypes. However, many promising treatments are on the horizon based on knowledge of molecular subtypes and key biomarkers of LAGC, such as microsatellite instability, HER2, Claudin 18.2, FGFR2, and PD-L1. This review will expand upon the discussion of current standard neoadjuvant and adjuvant therapies for LAGC and explore the ongoing and future clinical trials for novel therapies, with information obtained from searches in PubMed and ClinicalTrials.gov.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapybiomarkersgastric cancerimmunotherapylocally advancedneoadjuvant therapytargeted therapy

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
  • Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Division of Surgical Sciences, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA.

ORCID-Profile: Anna S Koerner, Sandra W Ryeom

Förderung

  • NCI NIH HHS
  • Herbert Irving Columba Cancer Center Support Grant
  • DeGregorio Family Foundation
  • Stand Up To Cancer Gastric Cancer Interception Research Team

Zitieren

APA

Koerner, A. S., Moy, R. H., Ryeom, S. W., & Yoon, S. S. (2023). The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer. Cancers, 15(16), 4114. https://doi.org/10.3390/cancers15164114

Vancouver

Koerner AS, Moy RH, Ryeom SW, Yoon SS. The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer. Cancers. 2023;15(16):4114. doi:10.3390/cancers15164114

BibTeX
@article{Koerner2023,
  author = {Koerner, Anna S and Moy, Ryan H and Ryeom, Sandra W and Yoon, Sam S},
  title = {The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {16},
  pages = {4114},
  doi = {10.3390/cancers15164114}
}
Kostenlos starten →